10 Small Cap Stocks with Potential to Rise 1000 Percent
Small-cap stocks have returned to the market’s risk conversation in 2026.
Allogene Therapeutics Inc. (ALLO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 6,793,620 | $16,576,432 | -44% | 0% |
| 2. | Two Sigma Advisors John Overdeck And David Siegel | 5,375,456 | $13,116,113 | +86% | 0.01% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 3,501,078 | $8,542,630 | +1% | 0.03% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 3,447,984 | $8,413,082 | +1108% | 0.01% |
| 5. | Millennium Management Israel Englander | 3,322,053 | $8,105,809 | +81% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.90 | 1,724,137 | $4,999,997.30 | 1,724,137 | 2024-05-16 | Filing | |
| $3.60 | 190 | $683.05 | 819,590 | 2024-01-30 | Filing | |
| $12.60 | 15,000 | $189,000.00 | 258,885 | 2022-01-12 | Filing | |
| $12.60 | 155,039 | $1,953,491.40 | 195,039 | 2022-01-12 | Filing | |
| $47.00 | 106,382 | $4,999,954.00 | 1,798,163 | 2020-06-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.31 | 9,586 | $22,143.66 | 124,517 | 2026-04-21 | Filing | |
| $2.50 | 2,867 | $7,167.50 | 195,338 | 2026-03-31 | Filing | |
| $2.47 | 4,835 | $11,942.45 | 198,205 | 2026-03-16 | Filing | |
| $2.47 | 47,763 | $117,974.61 | 5,150,599 | 2026-03-16 | Filing | |
| $2.60 | 7,132 | $18,543.20 | 203,040 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,032,040 | $49,792,410 | 20.85% | |
| 2. | 19,091,095 | $46,582,273 | 0% | |
| 3. | 18,716,306 | $45,667,787 | 1.24% | |
| 4. | 8,660,306 | $21,131,147 | 0% | |
| 5. | 8,379,840 | $20,446,810 | 0.02% |
News See All
Investors' Stock Portfolio: Top 10 Penny Stocks To Buy
Risk appetite, driven by artificial intelligence fervor, continues to drive sentiment in US equity markets.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript
Operator: Hello. Thank you for standing by, and welcome to Therapeutics First Quarter 26 Conference Call. After the speakers' presentation, there will be a question and answer session. Telephone.
9 Best Biotech Penny Stocks to Buy in 2026
On April 24, Drew Pettit, Citi US equity strategist, joined 'The Exchange' on CNBC to discuss the market fundamentals this year, with a positive outlook for the market as investors look past geopolitical...
10 Best Growth Stocks Under $10 to Invest In
On April 22, Andrew Slimmon, Morgan Stanley Investment Management senior portfolio manager, joined CNBC's 'Squawk Box' to discuss the current state of the market and its various influences.
10 Best Penny Stocks to Buy and Hold Under $5
Smaller companies have started to attract more attention on Wall Street.
10 Stocks Under $5 That Will Explode
On April 8, 2026, in an interview with Reuters, Matt Stucky, chief portfolio manager for equities at Northwestern Mutual Wealth Management Company, discussed his inclination toward small- and mid-cap ...
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout
On March 13, 2026, Biren Amin, an analyst at Piper Sandler, maintained an “Overweight” rating on Allogene Therapeutics, Inc.
10 Most Active Penny Stocks to Buy
The 2026 Iran conflict has resulted in a spike in volatility across markets, with the conflict expected to persist amid escalating geopolitical tensions. The broader investor sentiment is showing risk...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to Allogene Therapeutics, Inc. Fourth Quarter 2025 Conference Call.